Raloxifene vs Tamoxifen
FDA Approved vs FDA Approved
avoid Researched · 95% Both are SERMs that compete for the same estrogen receptors. Combining two SERMs provides no meaningful additive benefit for gynecomastia or PCT and increases the risk of side effects including thromboembolic events. Choose one SERM based on the clinical goal: raloxifene for gynecomastia, tamoxifen for HPTA recovery.
Molecular Data
Raloxifene Tamoxifen
Weight 473.58 Da 371.51 Da
Half-life ~28 hours ~5-7 days
Type Benzothiophene-derived selective estrogen receptor modulator Triphenylethylene-derived selective estrogen receptor modulator
Key Benefits
Raloxifene
01 Superior breast tissue estrogen receptor antagonism makes it the preferred SERM for gynecomastia reversal
02 No estrogen agonist activity in the uterus, avoiding the endometrial risks associated with tamoxifen
03 Estrogen agonist activity in bone preserves bone mineral density and reduces fracture risk
04 Lower overall thromboembolic risk compared to tamoxifen
05 Metabolized via glucuronidation rather than CYP2D6, avoiding the drug interaction concerns that affect tamoxifen
06 Simple once-daily oral dosing with a manageable 28-hour half-life
07 FDA-approved with decades of clinical safety data in postmenopausal women
Tamoxifen
01 Blocks estrogen receptor signaling in breast tissue, preventing and treating gynecomastia
02 Stimulates LH and FSH production by antagonizing hypothalamic estrogen receptors
03 Restores endogenous testosterone production during post-cycle therapy
04 Partial estrogen agonist activity in bone preserves bone mineral density
05 Extremely long half-life allows for flexible dosing schedules
06 Decades of clinical use with a well-characterized safety and efficacy profile
07 Oral administration with no injections or reconstitution required
Side Effects
Raloxifene
Hot flashes and increased sweating
Leg cramps and muscle spasms
Joint pain or stiffness
Peripheral edema (mild swelling in extremities)
Flu-like symptoms during initial weeks
Tamoxifen
Hot flashes and night sweats
Nausea or gastrointestinal discomfort
Mood swings, irritability, or emotional lability
Fatigue during initial weeks of use
Headache
Contraindications
History of deep vein thrombosis, pulmonary embolism, retinal vein thrombosis, or other venous thromboembolic events
Active or past history of stroke or transient ischemic attack
Known hypersensitivity to raloxifene hydrochloride or any excipients
Pregnancy or planned pregnancy (category X -- contraindicated)
Prolonged immobilization (e.g., post-surgical recovery, extended bed rest) due to elevated DVT risk
Severe hepatic impairment
History of deep vein thrombosis, pulmonary embolism, or other thromboembolic events
Known hypersensitivity to tamoxifen citrate or any excipients
Concurrent warfarin or coumarin-type anticoagulant therapy (increased bleeding risk)
Pregnancy or planned pregnancy (category D -- known teratogenic risk)
Pre-existing endometrial hyperplasia or uterine cancer
Severe hepatic impairment
Research Evidence
Raloxifene Tamoxifen
Status FDA Approved FDA Approved
References 4 studies 5 studies
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.